Gowri Vijayaraghavan
Overview
Explore the profile of Gowri Vijayaraghavan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
144
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Potter N, Miraki-Moud F, Ermini L, Titley I, Vijayaraghavan G, Papaemmanuil E, et al.
Leukemia
. 2018 Dec;
33(5):1113-1123.
PMID: 30568172
We used single cell Q-PCR on a micro-fluidic platform (Fluidigm) to analyse clonal, genetic architecture and phylogeny in acute myeloid leukaemia (AML) using selected mutations. Ten cases of NPM1c mutant...
2.
Brioli A, Melchor L, Titley I, Vijayaraghavan G, Stephens C, Zeisig A, et al.
Leuk Lymphoma
. 2014 Mar;
55(11):2665-8.
PMID: 24660850
No abstract available.
3.
Potter N, Ermini L, Papaemmanuil E, Cazzaniga G, Vijayaraghavan G, Titley I, et al.
Genome Res
. 2013 Sep;
23(12):2115-25.
PMID: 24056532
The development of cancer is a dynamic evolutionary process in which intraclonal, genetic diversity provides a substrate for clonal selection and a source of therapeutic escape. The complexity and topography...
4.
Alvares C, Schenk T, Hulkki S, Min T, Vijayaraghavan G, Yeung J, et al.
Br J Haematol
. 2011 Jun;
154(4):457-65.
PMID: 21689085
The efficacy of tyrosine kinase (TK) inhibitors on non-cycling acute myeloid leukaemia (AML) cells, previously shown to have potent tumourigenic potential, is unknown. This pilot study describes the first attempt...
5.
Yap T, Walton M, Hunter L, Valenti M, Brandon A, Eve P, et al.
Mol Cancer Ther
. 2010 Dec;
10(2):360-71.
PMID: 21191045
AKT is frequently deregulated in cancer, making it an attractive anticancer drug target. CCT128930 is a novel ATP-competitive AKT inhibitor discovered using fragment- and structure-based approaches. It is a potent,...